Pfizer Announces Positive Top-Line Results from Phase 3 Study in Patients with Moderate to Severe Atopic Dermatitis
Pfizer
PR-M05-19-NI-055May 20, 2019
Drug Development
Novartis Will Spend Up to More Than $1 Billion on an Eczema Candidate
Emilie Branch
Pharma's Almanac
PAO-M07-18-NI-017Jul 24, 2018